We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Thyroid Cancer Warning: What the Black Box Actually Means

Why the Warning Exists

You’ve seen it in advertisements. The FDA black box warning on GLP-1 medications such as semaglutide and tirzepatide is about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). If you’ve never heard of MTC, you’re not alone. It’s rare. But the warning is real, and it’s important to understand what it actually means for you.

The warning exists because of animal studies. In mice and rats given semaglutide, and in rats given tirzepatide, researchers saw a dose-dependent and duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures, meaning blood levels of the drug in the range seen in people taking it.[1][2] These findings are the basis for the boxed warning on the FDA-approved labels.

The critical caveat: the labels state that it is unknown whether these medications cause thyroid C-cell tumors, including MTC, in humans, because the human relevance of the rodent tumors has not been determined.[1][2] The FDA and the manufacturers state this uncertainty explicitly in the prescribing information.

The Actual Human Data

Researchers have studied thyroid cancer in people using GLP-1 medications, mostly through large observational studies of health records. These studies compare groups of people rather than randomly assigning a medication, so they can show an association but cannot prove cause and effect. Here’s what two large studies show.

A Scandinavian cohort study (Denmark, Norway, and Sweden, 2007-2021) compared about 145,000 people who started a GLP-1 medication with about 292,000 who started a different diabetes medication (a DPP-4 inhibitor). Over an average of 3.9 years, thyroid cancer rates were similar: 1.33 versus 1.46 cases per 10,000 person-years. The authors concluded GLP-1 use was not associated with a substantially increased risk of thyroid cancer; their data were consistent with no more than a 31% increase in relative risk. MTC was too rare in this study to draw a firm conclusion.[3]

A French nested case-control study of people with type 2 diabetes found that 1 to 3 years of GLP-1 use was associated with a higher risk of thyroid cancer overall and of MTC.[4] Like the Scandinavian study, it was observational and cannot show whether the medication caused the cancers.

The labels also note that cases of MTC have been reported after approval in people treated with liraglutide, another GLP-1 medication, and that these reports are not enough to establish or rule out a causal link.[1]

This doesn’t mean there is zero risk, and it doesn’t mean a risk has been shown. These studies followed people for only a few years, and both looked mainly at people with type 2 diabetes. The human question remains open, which is why the warning stays on the label.

What the Warning Actually Applies To

The FDA black box warning is written broadly, but it has very specific clinical contraindications.

GLP-1 medications are contraindicated (meaning they should not be used) in patients with:[1][2]

  • A personal history of medullary thyroid carcinoma
  • A family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

MEN 2 is a hereditary syndrome caused by mutations in the RET proto-oncogene that predispose people to several tumors, including medullary thyroid carcinoma. Some cases of MTC are hereditary as well, which is why family history matters. If you have MEN 2, a relative with MEN 2, or a relative with MTC, tell the provider who is evaluating you so they can account for it.

If you do not fall into one of these categories, you do not have the specific contraindication. The boxed warning still applies to you, but whether these medications raise MTC risk in people has not been established.

MTC vs. Other Thyroid Cancers

One source of confusion: patients often conflate medullary thyroid carcinoma with papillary thyroid cancer, which is the most common type of thyroid cancer. The black box warning is about C-cell tumors such as MTC, not papillary cancer. They are different diseases with different biology and different prognoses.

When you read about thyroid cancer and GLP-1 medications online, check which type is being discussed. Some studies report all thyroid cancers combined, which mostly means papillary cancer, and others report MTC separately.

Symptoms to Watch For

The labels tell prescribers to inform patients about symptoms of thyroid tumors.[1][2] If you are on a GLP-1 medication and develop any of the following, contact your provider:

  • A mass, lump, or swelling in your neck
  • Difficulty swallowing
  • Shortness of breath
  • Persistent hoarseness or a change in your voice

These symptoms are not specific to thyroid cancer. They can indicate other thyroid problems, infection, or completely unrelated conditions. But they warrant a provider evaluation while you’re on a GLP-1 medication.

Calcitonin is a hormone produced by thyroid C-cells. Significantly elevated calcitonin can be a sign of MTC. You might wonder: shouldn’t everyone on a GLP-1 medication have their calcitonin levels checked regularly?

The labels say routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for detecting MTC early in people taking these medications, and that it may lead to unnecessary procedures because calcitonin testing has low specificity and thyroid disease is common in the general population.[1][2] If calcitonin is measured and found to be elevated, or a thyroid nodule is found on exam or imaging, the labels say the person should be evaluated further. If you develop symptoms like those listed above, your provider may order calcitonin or imaging as part of that evaluation.

The Same Warning Applies to All Formulations

Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. They do not have their own FDA-reviewed labels or boxed warnings. They contain the same active ingredients involved in the rodent findings, so the boxed warning and contraindications on the FDA-approved labels are the most relevant reference whichever formulation you are considering.

Whoever prescribes it should review your personal and family history the same way for a compounded product as for a brand-name one. The contraindications are the same, and so are the symptoms to report.

Who This Actually Affects: A Practical Framework

Use this framework to think through whether the black box warning applies to your situation, then confirm it with a licensed provider.

The labels say not to use GLP-1 medications if you have:

  • A personal diagnosis of medullary thyroid carcinoma
  • A family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

The thyroid contraindication does not apply to you if:

  • You have no personal or family history of MTC
  • You do not have MEN 2

Even then, a GLP-1 medication may or may not be right for you for other reasons. Thyroid symptoms, other thyroid conditions, and a family history of other endocrine problems are worth raising, and a licensed provider decides whether a prescription is appropriate.

The Regulatory Context

A boxed warning is the most prominent warning the FDA places on a prescription drug label. Here, it reflects findings from animal studies along with the uncertainty about what they mean for people. The labels lay out what is known from the data available so prescribers and patients can make informed decisions.

The black box warning is an acknowledgment of the rodent findings and the uncertainty. It is not a determination that GLP-1 medications cause thyroid cancer in humans. It tells prescribers to review personal and family history, to counsel patients about the potential risk and symptoms, and not to prescribe the medication to people with a personal or family history of MTC or with MEN 2.

For patients without MEN 2 or a personal or family history of MTC, the warning still applies, but a human risk has not been established.

How the Process Should Work

At most telehealth programs and in-person practices, a licensed provider decides whether a prescription is appropriate. Before prescribing a GLP-1 medication, that provider should ask about your personal and family medical history, including any history of thyroid cancer, MTC, or MEN 2 in your family.

If you answer yes to any of these questions, the provider may:

  • Ask follow-up questions to clarify the diagnosis
  • Request medical records to confirm the diagnosis
  • Determine that GLP-1 is not appropriate for you
  • Discuss alternative treatment options

If the intake you are offered never asks about thyroid cancer or MEN 2, ask the provider about it directly before you start.

If you want to understand more about GLP-1 side effects overall, check out our GLP-1 side effects hub, which covers nausea, constipation, and other common effects with prevalence data from trials.

We also have detailed information on GLP-1 long-term side effects based on the SELECT trial and other sustained-use studies.

For other rare risks like pancreatitis, see our guide on GLP-1 pancreatitis risk. For how the FDA tracks reported side effects, see GLP-1 adverse events and FAERS data.

For a full list of all GLP-1 contraindications beyond thyroid history, see GLP-1 contraindications.

And if you’re just starting out, the GLP-1 Patient Guide covers everything from how the medication works to what to expect during your first month.


Citations

[1] FDA. Prescribing information for Wegovy (semaglutide) injection and tablets. Boxed Warning; sections 4 and 5.1 “Risk of Thyroid C-Cell Tumors”; section 13.1. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[2] FDA. Prescribing information for Zepbound (tirzepatide) injection. Boxed Warning; sections 4 and 5.1 “Risk of Thyroid C-Cell Tumors”; section 13.1. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[3] Pasternak B, Wintzell V, Hviid A, et al. “Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.” BMJ. 2024;385:e078225. https://pubmed.ncbi.nlm.nih.gov/38683947/

[4] Bezin J, Gouverneur A, Penichon M, et al. “GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.” Diabetes Care. 2023;46(2):384-390. https://pubmed.ncbi.nlm.nih.gov/36356111/

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. Label information on this page is from the FDA prescribing information revisions cited. Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency. Study results describe the people studied and are not a prediction for any individual; results vary. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Do GLP-1 medications cause thyroid cancer?
It is not known. The boxed warning on GLP-1 labels is based on studies in which rodents developed thyroid C-cell tumors at clinically relevant exposures. The labels say it is unknown whether the medications cause these tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent findings has not been determined. Observational studies in people have mixed results; a large Scandinavian cohort study found no substantially increased risk, while a French study found a higher risk after 1 to 3 years of use. Neither can prove cause and effect.
Who should not take GLP-1 medications because of the thyroid warning?
GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). For people without these personal or family histories, the boxed warning still applies, but it rests on rodent data whose human relevance has not been determined. A licensed provider should review your personal and family medical history before prescribing.
What symptoms should I watch for that might indicate a thyroid problem?
The labels list symptoms of thyroid tumors to report, such as a mass or lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness. Contact your provider if you notice any of these while on a GLP-1 medication. They are not specific to thyroid cancer, but they warrant evaluation.
Is the thyroid cancer warning different for compounded GLP-1 medications?
Compounded semaglutide and tirzepatide are not FDA-approved and do not have their own FDA-reviewed labels or boxed warnings. They contain the same active ingredients that the rodent findings involved, so the warning and contraindications on the FDA-approved labels (personal or family history of MTC, or MEN 2) are the most relevant reference. Talk with your provider about this before using any formulation.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.